Immune globulin (human) is under clinical development by Octapharma and currently in Phase II for Neuropathy. According to GlobalData, Phase II drugs for Neuropathy have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Immune globulin (human)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Immune globulin (human) overview
Human normal immunoglobulin (Octagam, Gamten, NewGam, Globiga, and Panzyga) is an immune sera preparation. Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. It is formulated as injectable solution for intravenous route of administration. Human normal immunoglobulin is used for the treatment of primary immunodeficiency syndromes such as congenital agammaglobulinemia and hypogammaglobulinemia, severe combined immunodeficiencies, Wiskott Aldrich syndrome, chronic lymphatic leukemia with severe secondary hypogammaglobulinemia and recurrent infections and children with congenital AIDS who have repeated bacterial infections. Panzyga is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
The drug candidate is under development for the treatment of small fiber neuropathy (SFN), chronic inflammatory demyelinating polyneuropathy (CIDP), and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was also under development for treatment of stiff-person syndrome, Alzheimer's disease, Guillain-Barre syndrome, relapsing remitting multiple sclerosis (RRMS), mild cognitive impairment, pediatric acute-onset neuropsychiatric syndrome, and Rasmussen’s encephalitis.
Octapharma overview
Octapharma is a human protein product manufacturer. The company focuses on developing and producing medicines through human proteins from human plasma and cell lines. It treats patients worldwide with products across immunotherapy, hematology, and critical care therapeutic areas. The company sources plasma from company-owned plasma donation centers and other external sources. Octapharma owns plasma donation centers in the US and Germany and owns production facilities in Austria, Germany, France, Mexico, and Sweden. Its production plants carry out plasma fractionation and purification, pharmaceutical production, research and development, product labeling, packaging, storage, and distribution. Octapharma is headquartered in Lachen, Switzerland.
For a complete picture of Immune globulin (human)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
